Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Female patients, age ≥ 18 years (women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception)~* Advanced or metastatic Her2-negative breast cancer, histologically confirmed~* At least one measurable lesion according to RECIST criteria (Version 1.1)~* Documented disease progression~* Patients with progression after anthracycline and/or taxane treatment(palliative or adjuvant)~* Life expectancy of at least 12 weeks~* Performance status 0-2~* Hematologic:~  * ANC (absolute neutrophil count) ≥ 1.5 x 109/L~ * Hemoglobin ≥ 9 g/dL~ * Platelets ≥ 100 x 109/L~* Liver Function:~  * Albumin ≥ 2.5 g/dL~ * Serum bilirubin ≤ 2 mg/dL~ * AST (Aspartate aminotransferase) and ALT (Alanine aminotransferase) ≤ 3 x ULN (Upper limit of Normal) without liver metastases~    * 5 x ULN if documented liver metastases~* Renal Function:~* Serum Creatinine ≤ 1.5 mg/dL OR Calculated Creatinine Clearance ≥ 40 mL/min~Exclusion Criteria:~* Pregnant or lactating women~* Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent~* Radiation of the target lesion within the last 4 weeks~* Active bacterial, viral or fungal infection~* Patients with clinically apparent brain metastases~* Known Positivity for HIV~* Positivity for Hepatitis B or C~* History of other malignancy; patients who have been disease-free for 5 years or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Concurrent cancer therapy (chemotherapy, immunotherapy, antihormonal or biologic therapy) or concurrent treatment with an investigational drug~* Antihormonal therapy must have been discontinued prior to start of treatment (if possible at least 3 weeks before)~* Known hypersensitivity to the study drugs capecitabine and bendamustine or their excipients~* Pretreatment with capecitabine (pretreatment with infusional 5-FU (Fluorouracil) in the adjuvant or neoadjuvant setting is allowed) or bendamustine~* Treatment with sorivudine or derivates e.g. brivudin (Mevir©) within the last 4 weeks before and during study treatment with capecitabine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine and Bendamustine (Type: EXPERIMENTAL): Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).